Skip to main content
  • About
  • News & Events
  • Careers
  • Contact
  • Subscribe
FR
Canada’s Drug Agency | Drugs, Health Technologies and Systems.
  • Find Reports
    • Programs & Initiatives
      • Appropriate Use
      • Canadian Medical Imaging Inventory
      • Drugs for Rare Diseases
      • Health Systems
      • Health Technology Reviews
      • Horizon Scans
      • Post-Market Drug Evaluation
      • Reimbursement Reviews
      • Scientific Advice
    • Methods
      • Conflict of Interest
      • Methodological Guidelines
      • Program Procedures
    • Tools & Publications
      • Common Acronyms
      • Evidence Bundles
      • HTA Excel Tools
      • Finding the Evidence: Literature Searching Tools in Support of Systematic Reviews
      • Canadian Journal of Health Technologies
    • Provide Input
      • Current Opportunities
      • Instructions
      • Procedures & Templates
    • Engage
      • Sponsor a Reimbursement Review
      • Request Scientific Advice
      • Request an Evidence Review
    • Community Involvement
      • Collaboration and Outreach
      • Patient Groups
      • Pan-Canadian Collaborative
Canada’s Drug Agency | Drugs, Health Technologies and Systems.
FR
  • Find Reports
  • Our Work
    • Programs & Initiatives
      • Advisory Panel: Pan-Canadian Prescription Drug List
      • Appropriate Use
      • Canadian Medical Imaging Inventory
      • Drugs for Rare Diseases
      • Health Systems
      • Health Technology Reviews
      • Horizon Scans
      • Post-Market Drug Evaluation
      • Reimbursement Reviews
      • Scientific Advice
    • Methods
      • Conflict of Interest
      • Methodological Guidelines
      • Program Procedures
    • Tools & Publications
      • Common Acronyms
      • Evidence Bundles
      • HTA Excel Tools
      • Finding the Evidence: Literature Searching Tools in Support of Systematic Reviews
      • Canadian Journal of Health Technologies
  • Get Involved
    • Provide Input
      • Current Opportunities
      • Instructions
      • Procedures & Templates
    • Engage
      • Sponsor a Reimbursement Review
      • Request Scientific Advice
      • Request an Evidence Review
    • Community Involvement
      • Collaboration and Outreach
      • Patient Groups
      • Pan-Canadian Collaborative
  • About
  • News & Events
  • Careers
  • Contact
  • Subscribe
Evidence Bundle
Evidence for Medical Imaging

Publicly Funded PET-CT Indications: A Pan-Canadian Comparison

Submitted by [email protected] on Mon, 08/29/2022 - 14:36
  • Read more about Publicly Funded PET-CT Indications: A Pan-Canadian Comparison

Publicly Funded PET-CT Indications: Comparison of Canada With Other Countries

Submitted by [email protected] on Mon, 08/29/2022 - 14:35
  • Read more about Publicly Funded PET-CT Indications: Comparison of Canada With Other Countries

Mobile CT and MRI Units in Canada, 2019-2020

Submitted by [email protected] on Mon, 08/29/2022 - 14:32
  • Read more about Mobile CT and MRI Units in Canada, 2019-2020

Mobile Imaging: The Benefits and Challenges

Submitted by [email protected] on Mon, 08/29/2022 - 14:31
  • Read more about Mobile Imaging: The Benefits and Challenges

The Future of PET-CT in Canada

Submitted by [email protected] on Mon, 08/29/2022 - 14:29
  • Read more about The Future of PET-CT in Canada

The Age of Imaging Equipment in Canada

Submitted by [email protected] on Mon, 08/29/2022 - 14:28
  • Read more about The Age of Imaging Equipment in Canada

The Procurement of Advanced Imaging Equipment: A Pan-Canadian Comparison

Submitted by [email protected] on Mon, 08/29/2022 - 13:58
  • Read more about The Procurement of Advanced Imaging Equipment: A Pan-Canadian Comparison

The Role of Neuroimaging in Drugs Targeting Amyloid-Beta in Alzheimer Disease: Part 1

Submitted by [email protected] on Mon, 08/29/2022 - 14:25
  • Read more about The Role of Neuroimaging in Drugs Targeting Amyloid-Beta in Alzheimer Disease: Part 1

The Role of Neuroimaging in Drugs Targeting Amyloid-Beta in Alzheimer Disease: Part 2

Submitted by [email protected] on Mon, 08/29/2022 - 14:23
  • Read more about The Role of Neuroimaging in Drugs Targeting Amyloid-Beta in Alzheimer Disease: Part 2

The Implementation Considerations of PET-CT

Submitted by [email protected] on Mon, 08/29/2022 - 14:17
  • Read more about The Implementation Considerations of PET-CT

Pagination

  • Page 1
  • Next page ››

Canada’s Drug Agency is a pan-Canadian health organization, created and funded by Canada’s federal, provincial, and territorial governments.

We provide Canada’s health system leaders with independent evidence and advice so they can make informed drug, health technology, and health system decisions, and we collaborate with national and international partners to enhance our collective impact. 

  • Reports
  • Contact
  • Careers
  • Help

Stay up to date on the latest from Canada’s Drug Agency by subscribing to our newsletter.

Already subscribed? Update your preferences.

  • visit us on facebook
  • visit us on linkedin
  • visit us on youtube
  • visit us on instagram

© 2025 Canadian Agency for Drugs and Technologies in Health

  • Privacy Policy
  • Terms of Use
  • Accessibility
  • Request for Archived Report
Back to Top